Trade PURETECH HEALTH PLC ORD 1P - PRTC CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0140 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023925% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.002007% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | GBP | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United Kingdom of Great Britain and Northern Ireland | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.59 |
| Open | 1.58 |
| 1-Year Change | 3.74% |
| Day's Range | 1.544 - 1.584 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Dec 20, 2024 | 1.5580 | -0.0200 | -1.27% | 1.5780 | 1.5840 | 1.5240 |
| Dec 19, 2024 | 1.5900 | -0.0600 | -3.64% | 1.6500 | 1.6500 | 1.5680 |
| Dec 18, 2024 | 1.6220 | 0.0200 | 1.25% | 1.6020 | 1.7080 | 1.5860 |
| Dec 17, 2024 | 1.6020 | -0.0760 | -4.53% | 1.6780 | 1.6840 | 1.5420 |
| Dec 16, 2024 | 1.7000 | 0.1000 | 6.25% | 1.6000 | 1.7680 | 1.6000 |
| Dec 13, 2024 | 1.6200 | -0.0200 | -1.22% | 1.6400 | 1.6580 | 1.5540 |
| Dec 12, 2024 | 1.6780 | 0.0380 | 2.32% | 1.6400 | 1.6920 | 1.6400 |
| Dec 11, 2024 | 1.6720 | 0.0140 | 0.84% | 1.6580 | 1.6780 | 1.6480 |
| Dec 10, 2024 | 1.6800 | -0.0160 | -0.94% | 1.6960 | 1.7060 | 1.6460 |
| Dec 9, 2024 | 1.7240 | 0.0180 | 1.06% | 1.7060 | 1.7240 | 1.6760 |
| Dec 6, 2024 | 1.6540 | 0.0560 | 3.50% | 1.5980 | 1.6640 | 1.5980 |
| Dec 5, 2024 | 1.6320 | -0.0280 | -1.69% | 1.6600 | 1.6720 | 1.5920 |
| Dec 4, 2024 | 1.6700 | 0.0180 | 1.09% | 1.6520 | 1.6820 | 1.6200 |
| Dec 3, 2024 | 1.6560 | -0.0160 | -0.96% | 1.6720 | 1.6820 | 1.6520 |
| Dec 2, 2024 | 1.6560 | 0.0100 | 0.61% | 1.6460 | 1.6640 | 1.6140 |
| Nov 29, 2024 | 1.6680 | -0.0020 | -0.12% | 1.6700 | 1.6720 | 1.6180 |
| Nov 28, 2024 | 1.6700 | 0.0320 | 1.95% | 1.6380 | 1.6960 | 1.6380 |
| Nov 27, 2024 | 1.6880 | 0.0540 | 3.30% | 1.6340 | 1.6980 | 1.6120 |
| Nov 26, 2024 | 1.6380 | -0.0440 | -2.62% | 1.6820 | 1.6940 | 1.6180 |
| Nov 25, 2024 | 1.7100 | 0.0100 | 0.59% | 1.7000 | 1.7260 | 1.6780 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Puretech Health plc Company profile
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines targeting serious diseases that result from dysfunctions in the nervous, immune, and gastrointestinal systems. The company is developing a digital medicine platform for the treatment and assessment of cognitive dysfunction across various neurological and psychiatric indications; therapies to treat a range of acute and chronic inflammatory disorders; microbiome-derived immune modulators for maternal and paediatric health; novel approach to oral delivery of biologics, vaccines, and other drugs; platform to address androgenetic alopecia; mechanotherapeutics to treat obesity, and other chronic diseases related to the gastrointestinal pathway; muscarinic receptor agonist programme for the treatment of psychosis and cognition, including schizophrenia and Alzheimer''s; monoclonal antibody-based therapeutic to treat pancreatic cancer and other solid tumors; voice-based technology platform for monitoring and diagnosing mental and physical medical conditions, such as depression, Alzheimer''s disease, multiple sclerosis, and Parkinson''s disease; platform and products that seek to explore and leverage the health potential of music; therapies for immune-mediated and infectious diseases based on rationally-defined consortium of human microbiome-derived bacteria; and novel antibody and cell therapies for treating cancer. It is also developing a milk exosome-based technology designed to enable the oral administration of biologics, nucleic acids, and complex small molecules; and a lipid prodrug technology to enable lymphatic targeting. In addition, the company''s medical device programme is developing a non-invasive neurostimulation treatment for psychiatric disorders, including depression and bipolar disorder. PureTech Health plc was incorporated in 2015 and is headquartered in Boston, Massachusetts.| Industry: | Biotechnology & Medical Research (NEC) |
6 Tide Street
Suite 400
BOSTON
MASSACHUSETTS 02210
US
News
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
22:39, 12 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
12:47, 5 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com